Patient with metastatic breast cancer, HER2-positive, trastuzumab- and pertuzumab-resistant responding to lapatinib | Zendy

Daniela Cianniello | Zendy; Roberta Caputo | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Patient with metastatic breast cancer, HER2-positive, trastuzumab- and pertuzumab-resistant responding to lapatinib

Author(s) -

Daniela Cianniello,

Roberta Caputo

Publication year - 2018

Publication title -

aboutopen

Language(s) - English

Resource type - Journals

ISSN - 2465-2628

DOI - 10.19156/abtpn.2018.0044

Subject(s) - pertuzumab , lapatinib , trastuzumab , medicine , capecitabine , metastatic breast cancer , oncology , tyrosine kinase inhibitor , breast carcinoma , breast cancer , cancer , colorectal cancer

Lapatinib is an intracellular tyrosine kinase inhibitor of EGFR (ErbB1) and HER2 (ErbB2) receptors, approved for the treatment of metastatic breast carcinoma pre-treated with anti-HER2 antibodies. We report the case of a 60-year-old woman diagnosed with metastatic breast neoplasm, HER2-positive, progressing after treatment with trastuzumab, pertuzumab and T-DM1, who obtained a regression of hepatic metastases after treatment with lapatinib-capecitabine (Oncology).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research